

Special Issue

Therapeutic Vaccination of HIV-Infected Patients 2.0

Message from the Guest Editors

In 2019, 38 million people worldwide were living with human immunodeficiency virus 1 (HIV-1), 1.7 million new infections were reported, and almost 1 million patients died of AIDS. Despite the efforts of numerous research teams all around the world, no effective HIV-1 vaccine is available to date. The extremely high genetic variability of the virus and its ability to suppress protective immune responses hinder the development of a vaccine based on conventional methodologies. Another obstacle is the lack of adequate laboratory models to test potential vaccines on human tissue in a high-throughput manner. In line with these considerations, we would like to encourage the submission of works on the recent advances in the development of novel therapeutic vaccines for the treatment of HIV to this Special Issue. Studies using vaccine immunotherapy, adoptive cell transfer, CAR-T cells, HIV-associated and HIV-specific antigen stimulation of immune/antigen-presenting cells, and the use of nucleic acid transfer are welcome. Adding new information about these subjects may improve the design and the efficiency of new therapeutic vaccination strategies of HIV.

Guest Editors

Dr. Wilfried Posch

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

Prof. Dr. Doris Wilflingseder

Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

Deadline for manuscript submissions

closed (30 May 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/59251

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).